Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Free Cash Flow (2016 - 2025)

Marimed (MRMD) has disclosed Free Cash Flow for 13 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 220.08% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 80.03% decrease, with the full-year FY2024 number at -$5.2 million, down 187.52% from a year prior.
  • Free Cash Flow was $2.1 million for Q3 2025 at Marimed, up from -$12000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.0 million in Q4 2023 to a low of -$10.4 million in Q4 2022.
  • A 5-year average of $895894.7 and a median of $1.0 million in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 388.98% in 2022, then skyrocketed 750.0% in 2025.
  • Marimed's Free Cash Flow stood at $4.4 million in 2021, then plummeted by 337.4% to -$10.4 million in 2022, then skyrocketed by 215.57% to $12.0 million in 2023, then crashed by 112.23% to -$1.5 million in 2024, then soared by 243.92% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Free Cash Flow are $2.1 million (Q3 2025), -$12000.0 (Q2 2025), and $1.0 million (Q1 2025).